Table 2.
Clinical prognostic factors for survival of total patients using univariate and multivariate analyses.
| Univariate | Multivariate | |||
| Characteristic | Median OS (IQR), months | P | Hazard ratio (95% CI) | P |
| Age (years) | 0.911 | |||
| ≤40 | 18.0 (7.0–29.0) | |||
| >40 | 17.0 (6.0–30.0) | |||
| The period from HIV diagnosis to admission (months) | 0.424 | |||
| ≤6 | 17.0 (7.5–31.5) | |||
| >6 | 12.0 (5.0–27.5) | |||
| The period from finding the mass to admission (months) | 0.314 | |||
| ≤1 | 11.0 (5.0–29.0) | |||
| >1 | 23.0 (9.7–30.0) | |||
| Histology | 0.285 | |||
| DLBCL | 16.0 (6.0–29.0) | |||
| BL | 23.0 (9.0–29.0) | |||
| CD4 cell count (cells/μL) | 0.020 | 2.660 (1.420–4.982) | 0.002 | |
| ≤100 | 8.0 (4.5–29.5) | |||
| >100 | 21.5 (8.6–29.7) | |||
| HAART | 0.869 | |||
| Administered | 20.0 (5.2–29.8) | |||
| Not administered | 16.0 (7.0–29.0) | |||
| Chemotherapy | <0.001 | 0.482 (0.261–0.892) | 0.020 | |
| Administered | 23.0 (10.0–30.0) | |||
| Not administered | 7.0 (3.0–27.5) | |||
| Axillary lymph nodes | 0.120 | |||
| Involved | 10.0 (6.0–28.0) | |||
| Uninvolved | 21.5 (7.0–29.2) | |||
| Cervical lymph nodes | 0.280 | |||
| Involved | 12.0 (4.0–27.0) | |||
| Uninvolved | 19.0 (7.0–29.0) | |||
| Mediastinal/hilar lymph nodes | 0.022 | 1.699 (1.019–2.833) | 0.042 | |
| Involved | 9.5 (5.0–24.5) | |||
| Uninvolved | 21.0 (7.0–30.0) | |||
| Abdominal pelvic and peritoneal lymph nodes | 0.710 | |||
| Involved | 10.0 (5.0–28.0) | |||
| Uninvolved | 18.0 (6.7–29.0) | |||
| Retroperitoneal lymph nodes | 0.560 | |||
| Involved | 11.0 (5.3–23.5) | |||
| Uninvolved | 19.0 (6.0–30.0) | |||
| Inguinal lymph nodes | 0.050 | |||
| Involved | 26.5 (20.7–34.5) | |||
| Uninvolved | 16.0 (6.0–29.0) | |||
| Gastrointestinal tract | 0.015 | 1.860 (1.120–3.100) | 0.210 | |
| Involved | 11.0 (5.6–26.0) | |||
| Uninvolved | 23.0 (7.0–30.0) | |||
| Urinary system organs | 0.550 | |||
| Involved | 16 (3–27) | |||
| Uninvolved | 18 (7–30) | |||
| Liver | <0.001 | 2.484 (1.453–4.247) | 0.001 | |
| Involved | 7.0 (4.0–17.0) | |||
| Uninvolved | 22.5 (9.0–30.5) | |||
| Lung | 0.680 | |||
| Involved | 22.5 (6.2–30.5) | |||
| Uninvolved | 17.0 (6.5–29.0) | |||
| Diameter of max. focus (mm) | 0.534 | |||
| <5 | 16.0 (5.5–29.0) | |||
| ≥5 | 19.5 (7.2–29.7) | |||
| Shape | 0.458 | |||
| Irregular | 14.5 (6.2–30.0) | |||
| Circular | 21.0 (7.0–28.0) | |||
| Fusion tendency | 0.796 | |||
| With | 17 (6–30) | |||
| Without | 19 (7–29) | |||
| Extracapsular infiltration | 0.032 | 1.750 (1.050–2.910) | 0.090 | |
| With | 12 (6–27) | |||
| Without | 24 (7–30) | |||
| Necrosis | 0.005 | 2.020 (1.214–3.360) | 0.007 | |
| With | 8.7 (3.6–27.0) | |||
| Without | 22.0 (9.0–30.0) | |||
| Texture | 0.139 | |||
| Heterogeneous | 13.0 (6.0–29.0) | |||
| Homogeneous | 22.0 (6.5–29.5) | |||
| Attenuation | 0.059 | |||
| Hypoattenuation | 8.0 (4.5–23.0) | |||
| Isoattenuation | 21.0 (7.0–30.0) | |||
| Hyperattenuation | 12.0 (3.0–30.0) | |||
| Enhancement scan texture | 0.793 | |||
| Heterogeneous | 13.0 (5.0–27.5) | |||
| Homogeneous | 15.0 (3.7–31.5) | |||
| Enhancement degree | 0.568 | |||
| Mild | 13.0 (5.0–29.0) | |||
| Moderate | 15.0 (5.5–28.5) | |||
BL: Burkitt's lymphoma; DLBCL: Diffuse large B-cell lymphoma; HAART: Highly active antiretroviral therapy; HIV: Human immunodeficiency virus; IQR: Interquartile range; OS: Overall survival. CI: confidence interval.